DK3430397T3 - Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner - Google Patents

Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner Download PDF

Info

Publication number
DK3430397T3
DK3430397T3 DK17711134.1T DK17711134T DK3430397T3 DK 3430397 T3 DK3430397 T3 DK 3430397T3 DK 17711134 T DK17711134 T DK 17711134T DK 3430397 T3 DK3430397 T3 DK 3430397T3
Authority
DK
Denmark
Prior art keywords
ingregation
phagocytose
mediated
antibody
assay
Prior art date
Application number
DK17711134.1T
Other languages
English (en)
Inventor
Carl Co
Svetlana Bergelson
Allyson Masci
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Application granted granted Critical
Publication of DK3430397T3 publication Critical patent/DK3430397T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5032Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on intercellular interactions
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/5055Cells of the immune system involving macrophages
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
DK17711134.1T 2016-03-14 2017-03-14 Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner DK3430397T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662308082P 2016-03-14 2016-03-14
PCT/EP2017/056031 WO2017157961A1 (en) 2016-03-14 2017-03-14 Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins

Publications (1)

Publication Number Publication Date
DK3430397T3 true DK3430397T3 (da) 2022-05-02

Family

ID=58347346

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17711134.1T DK3430397T3 (da) 2016-03-14 2017-03-14 Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner

Country Status (6)

Country Link
US (1) US11340225B2 (da)
EP (2) EP3430397B1 (da)
DK (1) DK3430397T3 (da)
MA (1) MA43723A (da)
PL (1) PL3430397T3 (da)
WO (1) WO2017157961A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
WO2017157961A1 (en) 2016-03-14 2017-09-21 Biogen International Neuroscience Gmbh Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
SG11202001281WA (en) 2017-08-22 2020-03-30 Biogen Ma Inc Pharmaceutical compositions containing anti-beta amyloid antibodies
KR102523019B1 (ko) * 2018-05-30 2023-04-18 내셔날 헬스 리서치 인스티튜트 항-a베타 항체 및 이의 용도
WO2020214963A1 (en) * 2019-04-18 2020-10-22 Genentech, Inc. Antibody potency assay
CN116348487A (zh) 2020-07-23 2023-06-27 欧萨尔普罗席纳有限公司 抗淀粉样β抗体
US20240101673A1 (en) 2021-02-03 2024-03-28 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2022217022A1 (en) 2021-04-10 2022-10-13 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
JP2024516631A (ja) 2021-04-23 2024-04-16 プロファウンドバイオ ユーエス カンパニー 抗cd70抗体、そのコンジュゲートおよびこれを使用する方法
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030028904A1 (en) * 2001-04-19 2003-02-06 Gumienny Tina L. Genes involved in engulfment of dying cells and cell migration
EP2436696B8 (en) * 2007-01-05 2017-12-13 University of Zurich Anti-beta-amyloid antibody and uses thereof
US7771957B2 (en) * 2007-10-19 2010-08-10 The Regents Of The University Of California Method for diagnosing alzheimer's disease
US8940276B2 (en) 2008-12-19 2015-01-27 Biogen Idec International Neuroscience Gmbh Human anti-alpha-synuclein antibodies
JP2014503178A (ja) 2010-10-11 2014-02-13 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗タウ抗体
PT2723379T (pt) 2011-06-23 2018-11-14 Univ Of Zuerich Moléculas de ligação anti-alfa-sinucleína
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
CN104159918B (zh) 2011-10-28 2019-09-13 生物国际神经***科学公司 Tdp-43特异性结合分子
SG10201705104UA (en) 2012-12-21 2017-07-28 Biogen Int Neuroscience Gmbh Human anti-tau antibodies
KR20180069839A (ko) * 2015-10-08 2018-06-25 자임워크스 인코포레이티드 카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도
WO2017157961A1 (en) 2016-03-14 2017-09-21 Biogen International Neuroscience Gmbh Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins

Also Published As

Publication number Publication date
EP4063858A1 (en) 2022-09-28
US20190079077A1 (en) 2019-03-14
US11340225B2 (en) 2022-05-24
EP3430397A1 (en) 2019-01-23
EP3430397B1 (en) 2022-02-23
WO2017157961A1 (en) 2017-09-21
MA43723A (fr) 2021-05-19
PL3430397T3 (pl) 2022-04-04

Similar Documents

Publication Publication Date Title
DK3430397T3 (da) Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner
DK3554681T3 (da) Fremgangsmåde til proteincorona-sensorarray til tidlig detektering af sygdomme
DK3455257T3 (da) Anti-pd-l1-antistoffer
CL2018000732A1 (es) Variantes optimizadas de anticuerpos anti-vegf.
DK3332006T5 (da) Hidtil ukendte anti-PD-L1-antistoffer
DK3313874T3 (da) Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering
DK3294764T3 (da) Kimæriske antigenreceptor sammensætninger
DK3274366T3 (da) Kimær antigenreceptor
DK3440703T3 (da) Waferskalaenhed til isolator-membran-isolatoranordninger til nanoporemåling
DK3473783T3 (da) Fremgangsmåde til fremstilling af gulvplader
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3563156T3 (da) Fremgangsmåde til separering af biomolekyler
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3597663T3 (da) Kimære antigenreceptorer af anti-cd70
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3287523T3 (da) Fremgangsmåde til sekretorisk fremstilling af protein
DK3014279T3 (da) Fremgangsmåde til bestemmelse af proteinaggregater under anvendelse af overflade-fida
DK3304093T3 (da) Validering af biomarkørmåling
DK3713928T3 (da) Hidtil ukendte bradykinin-b2-receptorantagonister
DK3464331T3 (da) Stabiliserede præfusions-rsv f-proteiner
DK3334457T3 (da) Humaniserede anti-CCR7-receptorantistoffer
DK3487443T3 (da) Fremgangsmåde til opmåling af en implantat-implantat-situation
DK3452513T3 (da) Humaniserede anti-il-ir3-antistoffer
DK3166611T3 (da) Fremgangsmåde til fremstilling af 4-alkoxy-3-hydroxypicolinsyrer
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin